Publications by authors named "Stephane Oudard"

100Publications

Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit.

Ann Intensive Care 2020 Oct 16;10(1):143. Epub 2020 Oct 16.

Service de Réanimation Médicale, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13613-020-00761-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567777PMC
October 2020

BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.

Bull Cancer 2020 Jun;107(5S):eS22-eS27

Department of Medical Oncology, Hôpital Européen Georges Pompidou, APHP. Centre - Université de Paris, Paris, France; Centre de Recherche des Cordeliers, Université Paris 5, Sorbonne Université, Inserm U1138, F-75006 Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(20)30283-6DOI Listing
June 2020

[Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer].

Bull Cancer 2020 Jun;107(5S):S24-S34

Service d'oncologie médicale, Hôpital européen Georges-Pompidou, APHP Centre - Université de Paris, 20, rue Leblanc, 75015 Paris, France; INSERM UMRS1138, Centre de recherche des Cordeliers, Université de Paris, 15, rue de l'École-de-Médecine, 75006 Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(20)30275-7DOI Listing
June 2020

Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice.

Clin Genitourin Cancer 2020 Oct 6;18(5):e510-e516. Epub 2020 Mar 6.

Bordeaux PharmacoEpi, University of Bordeaux, Bordeaux, France; Inserm CIC1401 & U1219, Bordeaux, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.02.003DOI Listing
October 2020

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib.

Clin Breast Cancer 2020 04 20;20(2):e192-e195. Epub 2020 Feb 20.

Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France; University Paris Descartes Paris 5, Sorbonne Paris Cite, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2020.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102668PMC
April 2020

Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials.

Eur J Cancer 2020 01 11;125:142-152. Epub 2019 Dec 11.

Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.10.029DOI Listing
January 2020

Pericardial effusion under nivolumab: case-reports and review of the literature.

J Immunother Cancer 2019 10 18;7(1):266. Epub 2019 Oct 18.

Immunologie Clinique, AP/HP, Hôpital Européen Georges Pompidou, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0760-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798500PMC
October 2019

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.

Clin Genitourin Cancer 2019 10 25;17(5):e981-e994. Epub 2019 May 25.

Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Inserm, UMR-1162, Génomique fonctionnelle des tumeurs solides, IUH, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.05.009DOI Listing
October 2019

[Treatment of metastatic prostate cancer: what recent progress?]

Rev Prat 2018 Sep;68(7):707-712

Service de cancérologie médicale, Hôpital européen Georges-Pompidou, AP-HP, université René-Descartes Paris-5, groupe hospitalier Ouest Parisien, Paris, France.

View Article

Download full-text PDF

Source
September 2018

Ten-year outcome of curative "exclusive" chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response.

Head Neck 2019 07 1;41(7):2190-2196. Epub 2019 Feb 1.

Department of Otorhinolaryngology - Head and Neck Surgery, Université Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou, Paris, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hed.25674
Publisher Site
http://dx.doi.org/10.1002/hed.25674DOI Listing
July 2019

Immunothérapie des cancers du rein.

Bull Cancer 2018 Dec;105 Suppl 1:S24-S34

Service d'oncologie médicale, Hôpital européen Georges-Pompidou, Paris, France; Immunothérapies et antiangiogéniques en oncologie, équipe 10 PARCC, INSERM U970, Sorbonne-Paris-Cité, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(18)30387-4DOI Listing
December 2018

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.

Clin Genitourin Cancer 2019 04 16;17(2):e235-e246. Epub 2018 Nov 16.

Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium; Inserm UMR1162 Génomique Fonctionnelle des Tumeurs Solides, Université Paris-5 René Descartes, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.11.002DOI Listing
April 2019

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges.

Kidney Cancer 2017 Nov 27;1(2):107-114. Epub 2017 Nov 27.

Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Radiology Department, Paris, France.

View Article

Download full-text PDF

Source
http://www.medra.org/servlet/aliasResolver?alias=iospress&am
Publisher Site
http://dx.doi.org/10.3233/KCA-170011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179123PMC
November 2017

Targeting Resident Memory T Cells for Cancer Immunotherapy.

Front Immunol 2018 27;9:1722. Epub 2018 Jul 27.

INSERM U970, Paris Cardiovascular Research Center (PARCC), Université Paris Descartes, Paris, France.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.01722
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.01722DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072845PMC
September 2019

Extreme hypomagnesemia: characteristics of 119 consecutive inpatients.

Intern Emerg Med 2018 Dec 27;13(8):1201-1209. Epub 2018 Jun 27.

Service de Médecine Interne, Internal medicine Department, Georges Pompidou European Hospital, AP-HP, 20 rue Leblanc, 75015, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11739-018-1898-7DOI Listing
December 2018

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

N Engl J Med 2018 Aug 3;379(5):417-427. Epub 2018 Jun 3.

From the Departments of Urology (A.M., M.-O.T.) and Medical Oncology (S.O.), Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Descartes, and Paris Descartes Necker-Cochin Clinical Research Unit, AP-HP (S.C.), Paris, the Department of Medical Oncology, Bordeaux University Hospital (A.R.), the Department of Medical Oncology, Hôpital Saint André, Centre Hospitalier Universitaire (CHU) de Bordeaux (M.G.-G.), and the Department of Urology, CHU de Bordeaux and Université de Bordeaux (J.-C.B.), Bordeaux, Biometrics Unit, Cancer Institute of Montpellier, University of Montpellier, Montpellier (S.T.), the Department of Urology, CHU Rangueil (J.-B.B.), and the Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole (C.C.), Toulouse, the Department of Urology, University of Rennes (K.B.), and the Department of Medical Oncology, Centre Eugene Marquis (B.L.), Rennes, the Department of Medical Oncology, Institut de Cancerologie de Lorraine, Vandoeuvre lès Nancy (L. Geoffrois), the Department of Medical Oncology, CHU Besançon, Oncologie, and Université de Franche-Comte, INSERM Unité Mixte de Recherche (UMR) 1098, Structure Fédérative de Recherche Ingénierie et Biologie Cellulaire et Tissulaire, Besançon (A.T.-V.), the Department of Urology, CHU François Mitterrand, Dijon (L.C.), the Department of Urology, CHU Strasbourg, Translational Medicine Federation Strasbourg, Strasbourg (H.L.), the Department of Urology, Gabriel Montpied Hospital, and Clermont Auvergne University, Clermont-Ferrand (L. Guy), the Department of Medical Oncology, Centre de Recherche en Cancerologie de Marseille, INSERM UMR 1068, Centre National de la Recherche Scientifique UMR 7258 and Institut Paoli-Calmettes (G.G.), and the Department of Urology, Hôpital la Conception (E.L.), Aix Marseille Université, Marseille, the Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Nantes (F.R.), the Department of Medical Oncology, CHU Bretonneau, and the Department of Medicine, Université François Rabelais, Tours (C.L.), the Department of Urology, Mont de Marsan General Hospital, Mont de Marsan (J.-J.P.), the Departments of Medical Oncology (C.T.) and Urology (T.L.), Hôpital Foch, Suresnes, the Department of Urology, Imagerie Adaptative Diagnostique et Interventionnelle INSERM Unité 1254, CHU de Nancy, Brabois (J.H.), the Department of Medical Oncology, Institut Gustave Roussy and Université Paris-Saclay, Villejuif (L.A., B.E.), and Université Versailles, St.-Quentin-en-Yvelines (T.L.) - all in France; the Department of Urology, Haukeland University Hospital (C.B.), and the Department of Clinical Medicine, University of Bergen (C.B.), Bergen, Norway; and the Department of Urology, Royal Free Hospital, London (M.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803675DOI Listing
August 2018

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients.

PLoS One 2018 6;13(4):e0195042. Epub 2018 Apr 6.

Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Department of Oncology, Hôpital Européen Georges Pompidou, Paris, France.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195042PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889159PMC
July 2018

[Tim-3: a novel biomarker and therapeutic target in oncology].

Med Sci (Paris) 2018 Mar 16;34(3):231-237. Epub 2018 Mar 16.

Inserm U970, université Paris Descartes Sorbonne Paris-Cité, Paris, France - Équipe labellisée Ligue contre le cancer, Paris, France - Hôpital européen Georges Pompidou, service d'immunologie biologique, 20, rue Leblanc, 75015 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/20183403011DOI Listing
March 2018

Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.

Clin Genitourin Cancer 2018 08 5;16(4):266-273. Epub 2018 Feb 5.

Laboratory of Experimental Oncology, Department of Oncology, University of Leuven, Leuven, Belgium; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.01.013DOI Listing
August 2018

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

N Engl J Med 2018 Apr 8;378(15):1408-1418. Epub 2018 Feb 8.

From the Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (M.R.S.); Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal (F.S.); Guy's, King's and St. Thomas' Hospitals, Great Maze Pond, London (S.C.); Georges Pompidou Hospital, Paris (S.O.); University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany (B.A.H.); Veterans Affairs Portland Health Care System, Portland, and Knight Cancer Institute, Oregon Health and Science University, Portland (J.N.G.); Spanish National Cancer Research Center, Madrid, and Hospitales Universitarios Virgen de la Victoria y Regional, Institute of Biomedical Research in Malaga, Malaga - both in Spain (D.O.); Centre for Personalised Nanomedicine, University of Queensland, Brisbane, Australia (P.N.M.); St. Mary's Hospital of Catholic University, Seoul, South Korea (J.Y.L.); Yokohama City University Medical Center, Yokohama, Japan (H.U.); Janssen Research and Development, Los Angeles (A.L.-G., G.C.T., B.M.E., Y.S., Y.C.P., W.R.R., M.K.Y.); and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco (E.J.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1715546DOI Listing
April 2018

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

J Clin Oncol 2018 03 8;36(8):765-772. Epub 2018 Jan 8.

Bernard Escudier, Institut Gustave Roussy, Villejuif; Stephane Oudard, Hôpital Européen Georges Pompidou, Paris; Frederic Rolland, Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes, Saint-Herblain, France; Thomas Powles, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University, Columbus, OH; Osvaldo Arén Frontera, Centro Internacional de Estudios Clinicos, Santiago, Chile; Piotr Tomczak, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznań, Poland; Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid, Spain; Leonard J Appleman, University of Pittsburgh Medical Center, Pittsburgh, PA; Harry Drabkin, Medical University of South Carolina, Charleston, SC; Daniel Vaena, University of Iowa Hospitals and Clinics, Iowa City, IA; Steven Milwee, Jillian Youkstetter, and Julie C. Lougheed, Exelixis, Inc., San Francisco, CA; Sergio Bracarda, Ospedale San Donato, Istituto Toscano Tumori (ITT), Arezzo, Italy; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804840PMC
March 2018

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

J Clin Oncol 2017 Oct 28;35(28):3189-3197. Epub 2017 Jul 28.

Stéphane Oudard, Georges Pompidou European Hospital, Rene Descartes University; Mustapha Chadjaa; Sanofi, Paris; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; Antoine Thiery-Vuillemin, Centre Hospitalier Universitaire Minjoz Besançon, Besançon, France; Lisa Sengeløv, Herlev Hospital, Herlev; Gedske Daugaard, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Steinbjørn Hansen, Odense University Hospital, Odense, Denmark; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Marie Hjälm-Eriksson, Karolinska University Hospital, Stockholm, Sweden; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Orazio Caffo, Santa Chiara Hospital, Trento, Italy; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; John Bernard, Sanofi, Cambridge, MA; Liji Shen, Sanofi, Bridgewater, NJ; and Oliver Sartor, Tulane Cancer Center, New Orleans, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1068DOI Listing
October 2017

Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?

Eur Urol Focus 2016 Oct 24;2(4):426-440. Epub 2015 Dec 24.

Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24054569150017
Publisher Site
http://dx.doi.org/10.1016/j.euf.2015.11.008DOI Listing
October 2016

A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer.

J Chromatogr B Analyt Technol Biomed Life Sci 2017 Jul 5;1058:102-107. Epub 2017 Apr 5.

Department of Pharmacokinetics and Pharmacochemisty, Hôpital Cochin, AP-HP, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jchromb.2017.04.014DOI Listing
July 2017

Supportive Care Organization in France: a national in-depth survey among patients and oncologists.

Support Care Cancer 2017 07 20;25(7):2111-2118. Epub 2017 Feb 20.

(AFSOS) Association Francophone pour les Soins Oncologiques de Support- French Speaking Association for Supportive Care in Cancer, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-017-3615-xDOI Listing
July 2017

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2017 06 1;15(3):350-355. Epub 2017 Feb 1.

Oncology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France; Association pour la Recherche sur les Thérapeutiques Innovantes en Cancérologie, Paris, France; U790 PARCC, European Georges Pompidou Hospital, René Descartes University, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.01.022DOI Listing
June 2017

Immunothérapie dans les cancers de la prostate.

Bull Cancer 2016 Nov;103 Suppl 1:S144-S150

Service de cancérologie médicale, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; CRC UMRS1138 EQ13, 15, rue de l'École-de-Médecine, 75006 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(16)30372-1DOI Listing
November 2016

Sunitinib in kidney cancer: 10 years of experience and development.

Expert Rev Anticancer Ther 2017 Feb 27;17(2):129-142. Epub 2016 Dec 27.

a Oncology Department , Georges Pompidou European Hospital , Paris , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1272415DOI Listing
February 2017

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.

Vaccines (Basel) 2016 Nov 3;4(4). Epub 2016 Nov 3.

INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, 75015 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/vaccines4040037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192357PMC
November 2016

First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis.

Crit Rev Oncol Hematol 2016 Nov 1;107:44-53. Epub 2016 Sep 1.

Department of Medical Oncology, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France; University of Paris-Est, Faculty of Medicine, Créteil, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428163019
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2016.08.012DOI Listing
November 2016

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

J Clin Oncol 2016 09 11;34(25):3005-13. Epub 2016 Jul 11.

Matthew Smith, Massachusetts General Hospital, Boston, MA; Johann De Bono, Royal Marsden Hospital, Sutton; Syed Hussain, University of Liverpool, Liverpool, United Kingdom; Cora Sternberg, San Camillo and Forlanini Hospitals, Rome; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-Istituto di Ricovero e Cura a Carattere Scientifico, Meldola; Giorgio Cruciani, Istituto Tumori Romagna, Lugo di Romagna, Italy; Sylvestre Le Moulec, Hôpital d'Instruction des Armées Val-de-Grâce; Stéphane Oudard, European Hospital Georges Pompidou and Paris Descartes University, Paris; Antoine Thiery-Vuillemin, Jean Minjoz Hospital, Besançon; Nadine Houédé, Institut de Cancérologie du Gard-Centre Hospitalier Universitaire Caremeau, Nîmes; Karim Fizazi, Institute Gustave Roussy, University of Paris Sud, Villejuif, France; Michael Krainer, Medical University of Vienna, Vienna, Austria; Andries Bergman, Netherlands Cancer Institute, Amsterdam; Ronald De Wit, Erasmus University Medical Center and Cancer Institute, Rotterdam, the Netherlands; Wolfgang Hoelzer, Praxis für Urologie; Kurt Miller, Charité-Universitätsmedizin Berlin, Berlin; Martin Bögemann, University of Muenster Medical Center, Muenster; Susan Feyerabend, Studienpraxis Urologie, Nürtingen; Arnulf Stenzl, University Hospital, Tübingen, Germany; Fred Saad, Centre Hospitalier de I'Université de Montréal, Montreal, Quebec, Canada; Elaine Lam, University of Colorado Anschutz Medical Campus, Aurora, CO; Jonathan Polikoff, Kaiser Permanente Medical Group, San Diego; David Ramies, Colin Hessel, and Aaron Weitzman, Exelixis, South San Francisco, CA; and Paul Mainwaring, Hematology and Oncology Clinics of Australia, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/34/25/3005.full.pdf
Web Search
http://dx.doi.org/10.1200/JCO.2015.65.5597DOI Listing
September 2016

A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.

Clin Cancer Res 2016 Aug 22;22(16):4133-44. Epub 2016 Mar 22.

INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France. Equipe Labellisée Ligue Contre le Cancer, Paris, France. Service d'Immunologie biologique, Hopital Européen Georges Pompidou-APHP, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0044DOI Listing
August 2016

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

J Clin Oncol 2016 05 7;34(14):1660-8. Epub 2016 Mar 7.

Thomas Powles, Queen Mary University of London, London; Christy Ralph, University of Leeds, Leeds; Janet E. Brown, University of Sheffield, Sheffield; Robert E. Hawkins, University of Manchester, Manchester, United Kingdom; Mark R. Lackner, Wei Lin, Bridget O'Keeffe, Yulei Wang, Shan Lu, Jill M. Spoerke, Ling Yuh Huw, Michelle Byrtek, Rui Zhu, and Joseph A. Ware, Genentech, South San Francisco, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Bernard Escudier, Institut Gustave Roussy, Villejuif; Alain Ravaud, Hospital Saint Andre, Bordeaux; Stéphane Oudard, University Paris Descartes, Paris, France; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; and Michael D. Staehler, University Hospital Munich-Grosshadern, Marchioninistrasse, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569691PMC
May 2016

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

Oncoimmunology 2015 Dec 7;4(12):e1049804. Epub 2015 Aug 7.

INSERM UMR_S 1138 Cancer; Immune Control and Escape; Cordeliers Research Centre ; Paris, France ; Université Paris Descartes; Sorbonne Paris Cité; UMR_S 1338; Cordeliers Research Centre ; Paris, France ; Sorbonne Universités; UPMC Univ Paris 06; UMR_S 1138; Cordeliers Research Centre ; Paris, France ; Assistance Publique-Hôpitaux de Paris; Hôpital Européen Georges Pompidou, Department of Biology , Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1049804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635888PMC
December 2015

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.

Invest New Drugs 2015 Dec 21;33(6):1267-70. Epub 2015 Oct 21.

Centre des cancers de la femme et recherche clinique, GH Paris Centre, site Hôtel-Dieu, 1 place du Parvis Notre-Dame, 75181, Paris cedex 04, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0297-4DOI Listing
December 2015

Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord-Stromal Tumors: A Systematic Review and Meta-analysis.

Int J Gynecol Cancer 2015 Nov;25(9):1593-8

From the *Department of Medical Oncology, Hôpital Européen Georges Pompidou; †University Paris Descartes, Sorbonne Paris Cité; ‡Department of Pneumology, Hôpital Européen Georges Pompidou; and §Women Cancer and Clinical Research Unit, Hôtel-Dieu, Paris, France.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00009577-201511000-000
Publisher Site
http://dx.doi.org/10.1097/IGC.0000000000000530DOI Listing
November 2015

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Oncoimmunology 2015 May 19;4(5):e1001236. Epub 2015 Mar 19.

Department of Medical Oncology; Hôpital Européen Georges Pompidou (AP-HP) ; Paris, France ; INSERM; PARCC (Paris Cardiovascular Research Center); Université Paris Descartes - Sorbonne Paris Cité ; Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2014.1001236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485845PMC
May 2015

The role of rechallenge with targeted therapies in metastatic renal-cell carcinoma.

Curr Opin Urol 2015 Sep;25(5):402-10

aOncology Department, European Hospital Georges Pompidou bOncology Department, Paris Descartes University, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000206DOI Listing
September 2015

The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors.

J Immunol 2015 Aug 1;195(4):1891-901. Epub 2015 Jul 1.

Commissariat à l'Energie Atomique, Institut de Biologie et de Technologies, Service d'Ingénierie Moléculaire des Protéines, Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique, Laboratoire d'Excellence Institut de Recherche Vaccinal, Gif Sur Yvette F-91191, France; Service d'Otorhinolaryngologie, Hopital Européen Georges Pompidou, Paris 75015, France;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1402548DOI Listing
August 2015